Pfizer

Pfizer is an American, multinational pharmaceutical and biotechnology corporation. The company was founded in 1849 by two German immigrants, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891), in New York, New York, United States.

Pfizer has the mission to fund programs that provide public benefit, advance medical care, and can improve patient outcomes. Their researchers preform 25,000 clinical tests everyday for pharmaceutical development and innovations.

Nowadays Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

Pfizer is a partner with the BaseLaunch startup accelerator. The BaseLaunch program receives applications in the fields of therapeutics, diagnostics, digital healthcare, healthcare services, therapeutic platforms, and medical technology.

Insilico Medicine and Pfizer entered into a research collaboration agreement. The agreement allows Pfizer to utilize Insilico Medicine's machine learning technology and Pandomics Discovery Platform to research potential therapeutic targets for a variety of diseases.

AMRA Medical and Pfizer's partnership works to investigate body fat distribution and muscle composition in a range of diseases using the UK Biobank registry. The partnership involves the body composition analysis of 100,000 individuals.

Pfizer's partnership with CytoReason gives them access to CytoReason's machine learning platform for drug discovery and development.

XtalPi Inc. and Pfizer's research collaboration focuses on developing a hybrid physics-and artificial intelligence-powered software platform for accurate molecular modeling of small molecules. The platform is intended to advance both companies capabilities in drug design and solid-form selection.

Pfizer and Distributed Bio entered an agreement to license Distributed Bio's SuperHuman Platform to Pfizer. The SuperHuman 2.0 antibody discovery platform will allow Pfizer to utilize the antibody library for screening activities against Pfizer-selected targets.

Domain Therapeutics and Pfizer entered into a collaboration agreement to asses Domain Therapeutics's bioSensAll platform. The bioSensAll platform defines signaling signatures for each wild-type and mutant receptors. Pfizer aims to use the platform to assess the impact of mutations on different signaling pathways engaged by g protein-coupled receptors.

Pfizer announced that they have identified certain anti-viral compounds that are under development which could be effective in treating the novel coronavirus SARS-CoV-2 responsible for COVID-19. They may enter a partnership with a third party company to screen and identify potential compounds by the end of March, 2020 in order to begin testing in April, 2020.

Pfizer is partnered with BioNTech for co-development and distribution of an mRNA vaccine against SARS-CoV-2 called BNT162.